George Clinical are pleased to announce that as of May 2, 2017, Vector Oncology CRO Division will be fully integrated into George Clinical’s portfolio of therapeutic expertise and services.

Important Announcement:
We are pleased to announce that as of May 2, 2017, Vector Oncology’s CRO Division will be fully integrated into George Clinical’s suite of therapeutic expertise and services. This exciting development will allow George Clinical to implement robust clinical oncology services and expertise throughout the Asia-Pacific region, the most populous region on Earth. Likewise, this acquisition will allow George Clinical to continue to broaden their networks and expand their traditional therapeutic strengths and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology, throughout North America and Europe. Please find the press release regarding this important announcement below.

Read The Press Release
If you have any further questions please contact:

Sean Hart
Managing Director George Clinical Inc
and Global Head of Late Phase Studies
George Clinical Pty.
T 913 706 6401 | 913 827 6441
E shart@georgeclinical.com
W www.georgeclinical.com